Identification

Name
Flurbiprofen
Accession Number
DB00712  (APRD00753)
Type
Small Molecule
Groups
Approved, Investigational
Description

Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.

Structure
Thumb
Synonyms
  • (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
  • 2-(2-Fluorobiphenyl-4-yl)propanoic acid
  • 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
  • 3-Fluoro-4-phenylhydratropic acid
  • FLP
  • Flurbiprofen
  • Flurbiprofene
  • Flurbiprofeno
  • Flurbiprofenum
  • S-flurbiprofen
External IDs
BTS 18 322 / FP 70 / FP 83 / U 27182
Product Ingredients
IngredientUNIICASInChI Key
Flurbiprofen SodiumZ5B97MU9K4Not AvailableAUAGTGKMTMVIKN-UHFFFAOYNA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ansaid Tablets 100 mgTablet100 mgOralPfizer1985-12-312013-07-25Canada
Ansaid Tablets 50 mgTablet50 mgOralPfizer1985-12-312013-07-25Canada
Flurbiprofen SodiumSolution / drops.3 mg/mLOphthalmicRebel Distributors1997-05-29Not applicableUs
Flurbiprofen SodiumSolution / drops.3 mg/mLOphthalmicPacific Pharma1997-05-29Not applicableUs
Flurbiprofen-100 Tab 100mgTablet100 mgOralPro Doc Limitee1992-12-312009-07-23Canada
Flurbiprofen-50 Tab 50mgTablet50 mgOralPro Doc Limitee1992-12-312009-07-23Canada
FrobenTablet100 mgOralAbbott1996-12-162008-06-06Canada
FrobenTablet50 mgOralAbbott1997-02-062008-06-06Canada
Froben SRCapsule, extended release200 mgOralAbbott1997-01-282008-06-06Canada
Froben Tab 100mgTablet100 mgOralOrganon Canada Ltd Ltee1986-12-311996-09-10Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-flurbiprofen Fc Tablets 100mgTablet100 mgOralApotex Corporation1991-12-31Not applicableCanada
Apo-flurbiprofen Fc Tablets 50mgTablet50 mgOralApotex Corporation1991-12-31Not applicableCanada
FlurbiprofenTablet, film coated100 mg/1OralStat Rx USA1994-06-20Not applicableUs
FlurbiprofenTablet, film coated50 mg/1OralMylan Pharmaceuticals1994-06-20Not applicableUs00378 0076 01 nlmimage10 634631a1
FlurbiprofenTablet, film coated100 mg/1Oralbryant ranch prepack1995-06-02Not applicableUs
FlurbiprofenTablet, film coated100 mg/1OralA S Medication Solutions1995-06-02Not applicableUs
FlurbiprofenTablet, film coated100 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-07Not applicableUs
FlurbiprofenTablet, film coated100 mg/1OralMylan Pharmaceuticals1994-06-20Not applicableUs
FlurbiprofenTablet, film coated100 mg/1OralTeva1995-06-02Not applicableUs00093 0711 01 nlmimage10 7e2b3f69
FlurbiprofenTablet, film coated100 mg/1OralPhysicians Total Care, Inc.1997-02-24Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Antiphlamine Pain RelievingPatch33 mg/51TopicalHanul Trading Co., Ltd.2015-09-01Not applicableUs
International/Other Brands
Acustop Cataplasma (Sang-A) / Adofeed (Lead Chemical) / Ansaid (Pfizer) / Antadys (Theramex) / Cebutid (Almirall) / Flurofen (Abbott Laboratories Ltd.) / Ocuflur (Allergan) / Stayban (Tokuhon) / Strefen (Reckitt Benckiser) / Strepfen (Reckitt Benckiser) / Strepsils (Reckitt Benckiser) / Strepsils Intensive (Reckitt Benckiser) / TransAct (Reckitt Benckiser) / Urbifen (General Pharma) / Zepolas (Mikasa Seiyaku)
Categories
UNII
5GRO578KLP
CAS number
5104-49-4
Weight
Average: 244.2609
Monoisotopic: 244.089957865
Chemical Formula
C15H13FO2
InChI Key
SYTBZMRGLBWNTM-UHFFFAOYSA-N
InChI
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
IUPAC Name
2-(3-fluoro-4-phenylphenyl)propanoic acid
SMILES
CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1

Pharmacology

Indication

Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.

Structured Indications
Pharmacodynamics

Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.

Mechanism of action

Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.

TargetActionsOrganism
UProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Fluribiprofen is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are reached 0.5 - 4 hours after oral administration.

Volume of distribution
  • 14 L [Normal Healthy Adults]
  • 12 L [Geriatric Arthritis Patients]
  • 10 L [End Stage Renal Disease Patients]
  • 14 L [Alcoholic Cirrhosis Patients]
  • 0.12 L/kg
Protein binding

> 99% bound, primarily to albumin. Binds to a different primary binding site on albumin than anticoagulants, sulfonamides and phenytoin.

Metabolism

Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4’-hydroxy-flurbiprofen. The 4’-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation.

Route of elimination

Flurbiprofen is poorly excreted into human milk. Following dosing with flurbiprofen, less than 3% of flurbiprofen is excreted unchanged in the urine, with about 70% of the dose eliminated in the urine as parent drug and metabolites. Renal elimination is a significant pathway of elimination of flurbiprofen metabolites.

Half life

R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours

Clearance
Not Available
Toxicity

LD50=10 mg/kg (orally in dogs).

Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of flurbiprofen. Flurbiprofen may increase blood pressure and/or cause fluid retention and edema. Use caution in patients with fluid retention or heart failure. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) may occur. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Although rarely documented in the case of flurbiprofen, oral propionic acid derivatives have been associated with a relatively high frequency of allergic reactions.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Flurbiprofen Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*3Not Available1075A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabFlurbiprofen may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Flurbiprofen can be decreased when combined with Abiraterone.Approved
AcebutololFlurbiprofen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Acemetacin.Approved
AcenocoumarolFlurbiprofen may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinFlurbiprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Flurbiprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.Approved
AliskirenFlurbiprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alminoprofen.Experimental
AlprenololFlurbiprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Flurbiprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Amcinonide.Approved
AmikacinFlurbiprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideFlurbiprofen may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Flurbiprofen can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinFlurbiprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodFlurbiprofen may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Anisodamine.Investigational
annamycinFlurbiprofen may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Antipyrine.Approved
Antithrombin III humanFlurbiprofen may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanFlurbiprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Apocynin.Investigational
ApramycinFlurbiprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Flurbiprofen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinFlurbiprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinFlurbiprofen may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanFlurbiprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololFlurbiprofen may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Atamestane.Investigational
AtenololFlurbiprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Flurbiprofen.Approved
BalsalazideFlurbiprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminFlurbiprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololFlurbiprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinFlurbiprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Flurbiprofen.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flurbiprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Flurbiprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololFlurbiprofen may decrease the antihypertensive activities of Betaxolol.Approved
BevantololFlurbiprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
BisoprololFlurbiprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinFlurbiprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololFlurbiprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bucillamine.Investigational
BucindololFlurbiprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bufexamac.Experimental
BufuralolFlurbiprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bumadizone.Experimental
BumetanideFlurbiprofen may decrease the diuretic activities of Bumetanide.Approved
BupranololFlurbiprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Flurbiprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Flurbiprofen.Experimental
CapecitabineThe metabolism of Flurbiprofen can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Flurbiprofen.Approved
CarbamazepineThe metabolism of Flurbiprofen can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Flurbiprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololFlurbiprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolFlurbiprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Castanospermine.Experimental
CeliprololFlurbiprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Flurbiprofen can be increased when it is combined with Ceritinib.Approved
CertoparinFlurbiprofen may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flurbiprofen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flurbiprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Flurbiprofen.Approved
CholecalciferolThe metabolism of Flurbiprofen can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flurbiprofen.Approved
CinoxacinFlurbiprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidFlurbiprofen may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Flurbiprofen.Vet Approved
CloranololFlurbiprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Flurbiprofen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Flurbiprofen can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Flurbiprofen.Experimental
CyclosporineFlurbiprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with D-Limonene.Investigational
Dabigatran etexilateFlurbiprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Flurbiprofen can be decreased when it is combined with Dabrafenib.Approved
DalteparinFlurbiprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidFlurbiprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanFlurbiprofen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinFlurbiprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Flurbiprofen.Experimental
DelavirdineThe metabolism of Flurbiprofen can be decreased when combined with Delavirdine.Approved
DesirudinFlurbiprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Flurbiprofen.Approved
DextranFlurbiprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Flurbiprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Flurbiprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Flurbiprofen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinFlurbiprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flurbiprofen.Approved, Vet Approved
DicoumarolFlurbiprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flurbiprofen.Approved
DihydrostreptomycinFlurbiprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Flurbiprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Flurbiprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Flurbiprofen.Approved
DosulepinThe metabolism of Flurbiprofen can be decreased when combined with Dosulepin.Approved
DoxorubicinFlurbiprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneFlurbiprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Flurbiprofen is combined with E-6201.Investigational
Edetic AcidFlurbiprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanFlurbiprofen may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Flurbiprofen can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Flurbiprofen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Flurbiprofen.Approved
EnoxacinFlurbiprofen may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinFlurbiprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Flurbiprofen.Experimental
EpanololFlurbiprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Epirizole.Approved
EpirubicinFlurbiprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneFlurbiprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Flurbiprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flurbiprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Equilin.Approved
EsmololFlurbiprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Estrone sulfate.Approved
Etacrynic acidFlurbiprofen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Flurbiprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateFlurbiprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etofenamate.Approved
EtravirineThe metabolism of Flurbiprofen can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flurbiprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Flurbiprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Feprazone.Experimental
Ferulic acidFlurbiprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Flurbiprofen.Approved
FleroxacinFlurbiprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Flurbiprofen.Approved, Withdrawn
FloxuridineThe metabolism of Flurbiprofen can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with fluasterone.Investigational
FluconazoleThe metabolism of Flurbiprofen can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fludrocortisone.Approved
FluindioneFlurbiprofen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlurbiprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Flurbiprofen can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Flurbiprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flurandrenolide.Approved
FluvastatinThe metabolism of Flurbiprofen can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Flurbiprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Flurbiprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxFlurbiprofen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFlurbiprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Flurbiprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Flurbiprofen.Approved
FosphenytoinThe metabolism of Flurbiprofen can be increased when combined with Fosphenytoin.Approved
FramycetinFlurbiprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideFlurbiprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateFlurbiprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinFlurbiprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinFlurbiprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Flurbiprofen.Approved, Withdrawn
GemfibrozilThe metabolism of Flurbiprofen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinFlurbiprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinFlurbiprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinFlurbiprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AFlurbiprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Flurbiprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinFlurbiprofen may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Flurbiprofen is combined with HE3286.Investigational
HeparinFlurbiprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Higenamine.Investigational
HydralazineFlurbiprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flurbiprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Flurbiprofen.Approved
Hygromycin BFlurbiprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Icatibant.Approved
IdarubicinFlurbiprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxFlurbiprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Flurbiprofen.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flurbiprofen.Approved
IndenololFlurbiprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Flurbiprofen can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flurbiprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Indoprofen.Withdrawn
INNO-206Flurbiprofen may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Flurbiprofen can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinFlurbiprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Istaroxime.Investigational
KanamycinFlurbiprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Flurbiprofen can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flurbiprofen.Approved
LabetalolFlurbiprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololFlurbiprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Flurbiprofen.Investigational
LeflunomideThe metabolism of Flurbiprofen can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinFlurbiprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanFlurbiprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololFlurbiprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinFlurbiprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Flurbiprofen.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Flurbiprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Flurbiprofen.Approved
LobeglitazoneThe metabolism of Flurbiprofen can be decreased when combined with Lobeglitazone.Approved
LonazolacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lornoxicam.Approved
LosartanThe metabolism of Flurbiprofen can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Flurbiprofen can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Flurbiprofen.Approved, Investigational
LumacaftorThe serum concentration of Flurbiprofen can be decreased when it is combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Flurbiprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Flurbiprofen can be decreased when combined with Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flurbiprofen.Approved
ME-609The risk or severity of adverse effects can be increased when Flurbiprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mefenamic acid.Approved
MelagatranFlurbiprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meloxicam.Approved, Vet Approved
MepindololFlurbiprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineFlurbiprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Flurbiprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololFlurbiprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen.Approved
MetoprololFlurbiprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideFlurbiprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinFlurbiprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Flurbiprofen can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Flurbiprofen can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Flurbiprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Flurbiprofen.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Flurbiprofen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurbiprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mycophenolic acid.Approved
NadololFlurbiprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinFlurbiprofen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatFlurbiprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naftifine.Approved
Nalidixic AcidFlurbiprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Flurbiprofen is combined with NCX 1022.Investigational
NeamineFlurbiprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinFlurbiprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinFlurbiprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nepafenac.Approved
NetilmicinFlurbiprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Flurbiprofen can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nitroaspirin.Investigational
NorfloxacinFlurbiprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Flurbiprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Olopatadine.Approved
OlsalazineFlurbiprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Flurbiprofen.Investigational
OmeprazoleThe metabolism of Flurbiprofen can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Orgotein.Vet Approved
OtamixabanFlurbiprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxaprozin.Approved
Oxolinic acidFlurbiprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololFlurbiprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Paramethasone.Approved
ParomomycinFlurbiprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Parthenolide.Investigational
PazufloxacinFlurbiprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinFlurbiprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololFlurbiprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateFlurbiprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Flurbiprofen.Approved
PhenindioneFlurbiprofen may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Flurbiprofen can be increased when combined with Phenobarbital.Approved
PhenprocoumonFlurbiprofen may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Flurbiprofen can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurbiprofen.Approved, Investigational
PindololFlurbiprofen may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidFlurbiprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinFlurbiprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideFlurbiprofen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pirfenidone.Investigational
Piromidic acidFlurbiprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurbiprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pirprofen.Experimental
PlazomicinFlurbiprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinFlurbiprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Flurbiprofen.Approved
PractololFlurbiprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Flurbiprofen.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Flurbiprofen can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Flurbiprofen can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Propacetamol.Approved
PropranololFlurbiprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Flurbiprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Flurbiprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Flurbiprofen.Vet Approved
Protein CFlurbiprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanFlurbiprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeFlurbiprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinFlurbiprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Flurbiprofen is combined with PTC299.Investigational
PuromycinFlurbiprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Flurbiprofen can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Flurbiprofen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Flurbiprofen.Approved
QuinineThe metabolism of Flurbiprofen can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Flurbiprofen.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flurbiprofen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol.Experimental, Investigational
ReviparinFlurbiprofen may increase the anticoagulant activities of Reviparin.Approved
RibostamycinFlurbiprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Flurbiprofen can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Flurbiprofen can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Risedronate.Approved, Investigational
RivaroxabanFlurbiprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinFlurbiprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinFlurbiprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinFlurbiprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Flurbiprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flurbiprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Flurbiprofen.Investigational
SecobarbitalThe metabolism of Flurbiprofen can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Flurbiprofen can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinFlurbiprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinFlurbiprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Flurbiprofen.Approved
SorafenibThe metabolism of Flurbiprofen can be decreased when combined with Sorafenib.Approved, Investigational
SotalolFlurbiprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CFlurbiprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinFlurbiprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinFlurbiprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Flurbiprofen.Approved
SpironolactoneFlurbiprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Flurbiprofen is combined with SRT501.Investigational
StreptomycinFlurbiprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinFlurbiprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Flurbiprofen can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Flurbiprofen can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Flurbiprofen can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Flurbiprofen.Approved
SulodexideFlurbiprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Flurbiprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Suxibuzone.Experimental
TacrolimusFlurbiprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Flurbiprofen.Approved
TalinololFlurbiprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Flurbiprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Flurbiprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flurbiprofen.Approved, Investigational
TemafloxacinFlurbiprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Flurbiprofen.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flurbiprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Teriflunomide.Approved
TertatololFlurbiprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Flurbiprofen can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Flurbiprofen can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tiludronic acid.Approved, Vet Approved
TimololFlurbiprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tixocortol.Approved
TobramycinFlurbiprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Flurbiprofen can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flurbiprofen.Approved
TopiroxostatThe metabolism of Flurbiprofen can be decreased when combined with Topiroxostat.Approved
TorasemideFlurbiprofen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Flurbiprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flurbiprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flurbiprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneFlurbiprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Flurbiprofen.Approved, Vet Approved
TrimethoprimThe metabolism of Flurbiprofen can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Triptolide.Investigational
TrovafloxacinFlurbiprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinFlurbiprofen may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Flurbiprofen.Approved
Valproic AcidThe metabolism of Flurbiprofen can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinFlurbiprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Flurbiprofen can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Flurbiprofen.Approved
VoriconazoleThe metabolism of Flurbiprofen can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFlurbiprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranFlurbiprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Flurbiprofen can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Flurbiprofen.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinFlurbiprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinFlurbiprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Yutaka Mizushima, Hiroyuki Okamoto, Shigetoshi Sugio, Kazumasa Yokoyama, Tadakazu Suyama, Masao Tohno, Makoto Okumura, Yoshiaki Konishi, Kiyonoshin Ichikawa, Katsuhiro Uchida, "Flurbiprofen derivative ophthalmic preparation." U.S. Patent US5171566, issued January, 1984.

US5171566
General References
  1. Geerts H: Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs. 2007 Feb;10(2):121-33. [PubMed:17285465]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Calapai G, Imbesi S, Cafeo V, Ventura Spagnolo E, Minciullo PL, Caputi AP, Gangemi S, Milone L: Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report. J Clin Pharm Ther. 2013 Aug;38(4):337-8. doi: 10.1111/jcpt.12073. Epub 2013 May 13. [PubMed:23668805]
  4. Mironov GG, Logie J, Okhonin V, Renaud JB, Mayer PM, Berezovski MV: Comparative study of three methods for affinity measurements: capillary electrophoresis coupled with UV detection and mass spectrometry, and direct infusion mass spectrometry. J Am Soc Mass Spectrom. 2012 Jul;23(7):1232-40. doi: 10.1007/s13361-012-0386-y. Epub 2012 Apr 28. [PubMed:22544663]
External Links
Human Metabolome Database
HMDB14850
KEGG Drug
D00330
PubChem Compound
3394
PubChem Substance
46505550
ChemSpider
3277
BindingDB
50074922
ChEBI
5130
ChEMBL
CHEMBL563
Therapeutic Targets Database
DAP000621
PharmGKB
PA449683
IUPHAR
4194
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Flurbiprofen
ATC Codes
M02AA19 — FlurbiprofenR02AX01 — FlurbiprofenM01AE09 — FlurbiprofenS01BC04 — Flurbiprofen
AHFS Codes
  • 28:08.04.92
  • 52:08.20
PDB Entries
Not Available
FDA label
Download (234 KB)
MSDS
Download (75 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentSurgery, Oral1
0Not Yet RecruitingDiagnosticPeri-implant Mucositis1
1CompletedNot AvailableDrug-drug Interaction Study1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedBasic ScienceRheumatoid Arthritis2
1CompletedDiagnosticDrug Interactions1
1CompletedDiagnosticHealthy Volunteers1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedTreatmentAnemias / Healthy Volunteers1
1CompletedTreatmentType 2 Diabetes Mellitus1
1, 2CompletedDiagnosticHealthy Volunteers1
2CompletedTreatmentAcute Sore Throat Pain1
2CompletedTreatmentPain1
2CompletedTreatmentPeriodontitis1
3CompletedTreatmentAcute Pharyngitis / Throat Pain1
3CompletedTreatmentPharyngitis2
4CompletedTreatmentPancreatic Stone Disease1
4CompletedTreatmentPostoperative Shivering1
4RecruitingTreatmentAcute Low Back Pain1
4RecruitingTreatmentComplications / Pain1
Not AvailableCompletedTreatmentPostoperative Sedation, Abdominal Surgery1
Not AvailableEnrolling by InvitationNot AvailableArthritis / Gout Acute / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableRecruitingNot AvailableDepressive State1
Not AvailableRecruitingTreatmentPostoperative Sedation,Gastrectomy, Enhanced Recovery After Surgery1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Theragen inc
  • Bausch and lomb inc
  • Allergan pharmaceutical
Packagers
Dosage forms
FormRouteStrength
PatchTopical33 mg/51
TabletOral100 mg
TabletOral50 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
Solution / dropsOphthalmic.242 mg/mL
Capsule, extended releaseOral200 mg
Solution / dropsOphthalmic.3 mg/mL
LiquidOphthalmic0.03 %
Prices
Unit descriptionCostUnit
Ocufen 0.03% Solution 2.5ml Bottle22.7USD bottle
Flurbiprofen powder20.9USD g
Flurbiprofen Sodium 0.03% Solution 2.5ml Bottle15.99USD bottle
Ocufen 0.03% eye drops10.63USD ml
Flurbiprofen 0.03% eye drop4.37USD ml
Ansaid 100 mg tablet2.1USD tablet
Flurbiprofen 100 mg tablet1.08USD tablet
Flurbiprofen 50 mg tablet0.8USD tablet
Ansaid 50 mg Tablet0.58USD tablet
Apo-Flurbiprofen 100 mg Tablet0.37USD tablet
Novo-Flurprofen 100 mg Tablet0.37USD tablet
Nu-Flurbiprofen 100 mg Tablet0.37USD tablet
Apo-Flurbiprofen 50 mg Tablet0.27USD tablet
Novo-Flurprofen 50 mg Tablet0.27USD tablet
Nu-Flurbiprofen 50 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)110-111 °CAdams, S.S., Bernard, J., Nicholson, J.S. and Blancafort, A.R.; U.S. Patent 3,755,427; Aug. 28, 1973; assigned to The Boots Company Ltd.
water solubility8 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.16HANSCH,C ET AL. (1995)
logS-4.49ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0249 mg/mLALOGPS
logP3.57ALOGPS
logP3.94ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.42ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity67.29 m3·mol-1ChemAxon
Polarizability25.23 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9824
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.76
P-glycoprotein inhibitor INon-inhibitor0.9061
P-glycoprotein inhibitor IINon-inhibitor0.9739
Renal organic cation transporterNon-inhibitor0.912
CYP450 2C9 substrateNon-substrate0.7247
CYP450 2D6 substrateNon-substrate0.9249
CYP450 3A4 substrateNon-substrate0.7205
CYP450 1A2 substrateInhibitor0.8663
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9546
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9674
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8752
Ames testNon AMES toxic0.9659
CarcinogenicityNon-carcinogens0.5554
BiodegradationNot ready biodegradable0.9861
Rat acute toxicity3.1121 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9849
hERG inhibition (predictor II)Non-inhibitor0.9116
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (126 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002b-0900000000-1791423706be24cc354b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002b-0900000000-1c9889f5fc33443c7b3b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-2900000000-d74a9b309815da3ba05d
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenylpropanoic acids / Monocyclic monoterpenoids / Aromatic monoterpenoids / Fluorobenzenes / Aryl fluorides / Monocarboxylic acids and derivatives / Carboxylic acids / Organofluorides / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Biphenyl / 2-phenylpropanoic-acid / P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Fluorobenzene / Halobenzene / Aryl halide / Aryl fluoride
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
fluorobiphenyl (CHEBI:5130)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Rieke CJ, Mulichak AM, Garavito RM, Smith WL: The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. J Biol Chem. 1999 Jun 11;274(24):17109-14. [PubMed:10358065]
  2. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000 May;293(2):417-25. [PubMed:10773011]
  3. Kurahashi K, Shirahase H, Nakamura S, Tarumi T, Koshino Y, Wang AM, Nishihashi T, Shimizu Y: Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S21-5. [PubMed:11811354]
  4. Klegeris A, McGeer PL: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging. 2002 Sep-Oct;23(5):787-94. [PubMed:12392782]
  5. Droge MJ, van Sorge AA, van Haeringen NJ, Quax WJ, Zaagsma J: Alternative splicing of cyclooxygenase-1 mRNA in the human iris. Ophthalmic Res. 2003 May-Jun;35(3):160-3. [PubMed:12711844]
  6. Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI: Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochem Res. 2007 Nov;32(11):1857-67. Epub 2007 Jun 12. [PubMed:17562170]
  7. Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep. 2008 Sep-Oct;60(5):692-8. [PubMed:19066416]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Bayly CI, Black WC, Leger S, Ouimet N, Ouellet M, Percival MD: Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12. [PubMed:10091674]
  2. van Haeringen NJ, van Sorge AA, Carballosa Core-Bodelier VM: Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. J Ocul Pharmacol Ther. 2000 Aug;16(4):353-61. [PubMed:10977131]
  3. Smith T, McCracken J, Shin YK, DeWitt D: Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (cyclooxygenase-2). J Biol Chem. 2000 Dec 22;275(51):40407-15. [PubMed:11006278]
  4. Hinz B, Brune K, Rau T, Pahl A: Flurbiprofen enantiomers inhibit inducible nitric oxide synthase expression in RAW 264.7 macrophages. Pharm Res. 2001 Feb;18(2):151-6. [PubMed:11405284]
  5. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000 May;293(2):417-25. [PubMed:10773011]
  6. Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI: Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochem Res. 2007 Nov;32(11):1857-67. Epub 2007 Jun 12. [PubMed:17562170]
  7. Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep. 2008 Sep-Oct;60(5):692-8. [PubMed:19066416]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Aarons L, Khan AZ, Grennan DM, Alam-Siddiqi M: The binding of flurbiprofen to plasma proteins. J Pharm Pharmacol. 1985 Sep;37(9):644-6. [PubMed:2867185]
  2. Takla PG, Schulman SG, Perrin JH: Measurement of flurbiprofen-human serum albumin interaction by fluorimetry. J Pharm Biomed Anal. 1985;3(1):41-50. [PubMed:16867708]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:43